In the BioHarmony Drug Report Database
Riociguat
Adempas (riociguat) is a small molecule pharmaceutical. Riociguat was first approved as Adempas on 2013-10-08. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension. It is known to target guanylate cyclase soluble subunit alpha-1, guanylate cyclase soluble subunit beta-1, and guanylate cyclase soluble subunit alpha-2. Adempas’s patents are valid until 2034-02-18 (FDA).
Trade Name
|
Adempas |
|---|---|
Common Name
|
riociguat |
ChEMBL ID
|
CHEMBL2107834 |
Indication
|
pulmonary hypertension |
Drug Class
|
Guanaline cyclase activator |
Image (chem structure or protein)